----

----

|              DELAWARE |                      41-1311718 |
|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

|        (State or other jurisdiction of incorporation or organization) |                      (I.R.S. Employer I.D. No.) |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| Large accelerated filer o | Accelerated filer o              |
|---------------------------|----------------------------------|
| Non-accelerated filer o   | Smaller reporting company þ |

| Class                                  | Shares Outstanding as of March 31, 2009 |
|----------------------------------------|-----------------------------------------|
| Class A Common Stock, $0.001 par value | 30,406,246                              |
| Class B Common Stock, $0.001 par value | 5,361,876                               |

----

| Part I   |                                                                                                               |      |
|----------|--------------------------------------------------------------------------------------------------------------------|-----------|
| Item 1.  | Business Overview                                                                                                  |   4  |
| Item 1A. | Risk Factors                                                                                                       |   19 |
| Item 1B. | Unresolved Staff Comments                                                                                          |   42 |
| Item 2.  | Properties                                                                                                         |   42 |
| Item 3.  | Legal Proceedings                                                                                                  |   43 |
| Item 4.  | Submission of Matter to a Vote of Security Holders                                                                 |   43 |
|     |                                                                                                               |      |
| Part II  |                                                                                                               |      |
| Item 5   | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |   43 |
| Item 6   | Selected Financial Data                                                                                            |   46 |
| Item 7   | Management’s Discussion and Analysis of Financial Condition and Results of Operation                         |   46 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk                                                         |   62 |
| Item 8.  | Financial Statements and Supplementary Data                                                                        |   63 |
| Item 9   | Changes in and Disagreements With Accountants on Accounting and Financial Disclosures                              |   86 |
| Item9AT. | Controls and Procedures                                                                                            |   86 |
| Part III |                                                                                                               |      |
| Item 10. | Directors, Executive Officers and Corporate Governance                                                        |   89 |
| Item 11. | Executive Compensation                                                                                             |   91 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                     |   92 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence                                          |   92 |
| Item 14. | Principal Accounting Fees and Services                                                                             |   93 |
|     |                                                                                                               |      |
| PART IV  |                                                                                                               |      |
| Item 15. | Exhibits , Financial Statement Schedules                                                                           |   93 |
|     | Signatures                                                                                                         |   96 |

| (i)   | Amended Part 1, Business Overview, Customer Dependence to correct that the Company is not “solely dependent on a few major customers” to conform with the disclosure requirements of Item 101(c)(1)(vii) of Regulation S-K and paragraph 39 of SFAS 131.  The Company does not have any customer that accounted for 10% or more of the consolidatedrevenue of the Company for the year ended December 31, 2008. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Amended Report of Independent Registered Public Accounting Firm to comply with the disclosure requirements of Rule 2-02(a)(4) of Regulation S-X to properly identify the specific years for which the report is issued. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | Amended Form 10-K on September 18, 2009 to correct for minor reclassifications to the Company’s balance sheet that were made to the December 31, 2007 audited financials in order to conform to the December 31, 2008 financial statement presentation. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | Amended the Notes to the Consolidated Financial Statements with regard to the Net deficit acquired in Anywhere MD to provide the purchase price allocation and disclosures required by paragraph 51 of SFAS 141. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | Amended the cash flow for the year ended December 31, 2007 that was presented in the 10K filed for year ending December 31, 2008 to reflect the proceeds of $1,027,831 as a financing activity that was improperly classified as operating activities. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vi)   | Amended the Notes to the Consolidated Financial Statements to identify the accounting literature that the “Minority Interest” amount and classification is based.  This classification is based upon ARB 51 “Consolidated Financial Statements”, which addresses the presentation of consolidated net income attributable to theparent and to the minority interest be clearly identified and presented on the face of the consolidated statement of income. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vii)   | Amended the Notes to the Consolidated Financial Statements, to provide the appropriate disclosure pursuant to paragraph 51 of SFAS 141, and the purchase price allocation with respect to the acquisition of Anywhere MD. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (viii)   | Amended the Notes to the Consolidated Financial Statements, to provide disclosure with respect to the Company’s identification and valuation of the AutoDOC software acquired in connection with the acquisition of Anywhere MD pursuant to paragraph 39 of SFAS 141. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ix)   | Amended the Notes to the Consolidated Financial Statements, to clarify and describe  the Company’s revenue recognition policy presented in the footnotes to the financial statements. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (x)   | Amended Item 9., Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. To comply with the disclosure requirements of Item 304 under Regulation S-K that there have been no disagreements or changes with the Company’s principal accounting firm. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (xi)   | Amended Note 9, Stockholders Equity, of the Consolidated Financial Statements to comply with the disclosures requirements of paragraph 64 of SFAS (123)R and subparagraphs (a) through (k) of paragraph A240. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (xii)   | Amended Item 9A(T),                                                      Controls andProcedures, to specifically address the requirements of Item 308T(b) of Regulation S-K that the annual report does not include an attestation report of the company’s registered public accounting firm regarding internal control over financial reporting and that management’s report was not subject to attestation by the company’s registered public accounting firm. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (xiii)   | Amended Item 9A(T),                                                      Controls andProcedures , to address the requirements of Item 308T(b) of Regulation S-K, that specifically requires disclosure of any change in your internal control over financial reporting that occurred during your last fiscal quarter (your fourth fiscal quarter in the case of your annual report) that has materially affected, or is reasonably likely to materially affect, your internal control over financial reporting. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (xiv)   | Filed currently dated certifications of the Company’s Chief Executive Officer and Chief Financial Officer as required under the Sarbanes-Oxley Act of 2002. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

Item 

----

----

| ·   | Currently, out of the estimated 600,000 physicians in the U.S., only 15-20% are estimated to have employed EHRs for their practice. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| ·   | This market is expected to grow significantly in the next several years as legislation and federal directives drive EHR adoption among physicians. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | The Bush Administration mandated that physicians switch all patient records to electronic form by 2014.  The mandate has received bi-partisan support from Congress and President Obama; |
|--------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | Medicare Electronic Medication and Safety Protection Act provides financial incentives for physicians to use e-prescribing systems that have current year CCHIT certification; |
|--------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | Medicare Prescription Drug, Improvement, and Modernization Act of 2003 permits hospitals and other organizations to provide e-prescribing and EHR software, information technology and training services to physicians; and |
|--------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | Private and public initiatives for healthcare IT adoption have currently made available more than $700 million.  The majority of subsidies and grants require current year CCHIT certification. |
|--------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | -   More than $20 billion was provided for the adoption of healthcare IT in early 2009 |
|--------|-------------------------------------------------------------------------------------------------------|

----

| ·   | The Company has received endorsements from one of the largest medical associations in the U.S. as well as four New York based medical societies. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   |  The Company continues to form valuable strategic partnerships with imaging centers, laboratories, RHIO’s and other facilities through the integration of their systems with the Company’s EHR. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The Company’s value-added partners provide a “captive” base of physicians as customers for the Company’s products. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The Company has a focused sales and marketing effort underway to leverage this prime access opportunity to reach these physicians. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The primary barrier to EHR adoption among physicians is cost.  The Company offers an attractive value proposition through MedLink EHR and EHR Lite.  EHR Lite provides physicians with basic EMR functionality at no upfront cost to the physician, creating a sticking point for later full EHR conversion. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The Company’s EHR is priced below competing products with similar services. |
|--------------------|-----------------------------------------------------------------------------------|

| ·   | Quick deployment of the Company’s EHR, makes the product very attractive to physicians and counterparties. |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| ·   | The Company’s EHR was one of 8 products which received full certification in October, 2008. |
|--------------------|---------------------------------------------------------------------------------------------------|

| ·   | This certification creates a tremendous competitive advantage for the Company in its targeted customer base, the small to medium sized physician office marketplace, as financial incentives are available to providers who use a 2008 CCHIT certified EHR product. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | 2% in fiscal year 2009 and 2010 |
|--------------------|---------------------------------|

| ·   | 1% in 2011 and 2012 |
|--------------------|---------------------|

| ·   | 0.5% in 2013 |
|--------------------|--------------|

----

| ·   | 1% payment cut in 2012 |
|--------------------|------------------------|

| ·   | 1.5% payment cut in 2013 |
|--------------------|--------------------------|

| ·   | 2% in subsequent years |
|--------------------|------------------------|

----

----

----

----

----

|                       |   |   |    |   | Less than |   |    |   |   |   |
|----------------------------|--------|--------|---------|--------|-----------|--------|---------|--------|--------|--------|
|                       | Total  |   | 1 year  |   | 1-3 years |
|                       |   |   |    |   |      |   |    |   |   |
| Operating Lease Obligation |   | $      | 850,992 |   |      | $      | 129,500 |   |   | $      | 460,032 |   |

----

----

----

----

----

----

Item 

----

----

----

----

----

----

|         | • |   | the performance of our software and our ability to promptly and efficiently address software performance shortcomings or warranty issues;         |
|--------------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|
|    | • |   | the cost, timeliness and outcomes of our software development and implementation efforts, including expansion of our development center in India; |
|    | • |   | the timing, size and complexity of our software sales and implementations;                                                                        |
|    | • |   | healthcare industry conditions and the overall demand for healthcare information technology;                                                      |
|    | • |   | variations in periodic software license revenues;                                                                                                 |
|    | • |   | the financial condition of our clients and potential clients;                                                                                     |
|         | • |   | market acceptance of new services, software and software enhancements introduced by us or our competitors;                                        |
|         | • |   | client decisions regarding renewal or termination of their contracts;                                                                             |

|         | • |   | software and price competition;                                                                                        |
|--------------|---------|--------|------------------------------------------------------------------------------------------------------------------------|
|    | • |   | investment required to support our international expansion efforts;                                                    |
|    | • |   | personnel changes and other organizational changes and related expenses;                                               |
|    | • |   | significant judgments and estimates made by management in the application of generally accepted accounting principles; |
|    | • |   | healthcare reform measures and healthcare regulation in general;                                                       |
|    | • |   | lower investment returns due to recent disruptions in U.S. and international financial markets; and                    |
|    | • |   | fluctuations in general economic and financial market conditions, including interest rates.                            |

----

----

----

|         | • |   | The anticipated benefits from the acquisition may not be achieved, including as a result of loss of customers or personnel of the target.                                                                                                                                                          |
|--------------|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | • |   | The identification, acquisition and integration of acquired businesses require substantial attention from management. The diversion of management’s attention and any difficulties encountered in the transition process could hurt our business.                                            |
|    | • |   | The identification, acquisition and integration of acquired businesses requires significant investment, including to harmonize product and service offerings, expand management capabilities and market presence, and improve or increase development efforts and software features and functions. |
|    | • |   | In future acquisitions, we could issue additional shares of our common stock, incur additional indebtedness or pay consideration in excess of book value, which could dilute future earnings.                                                                                                      |
|    | • |   | Acquisitions also expose us to the risk of assumed known and unknown liabilities.                                                                                                                                                                                                                  |
|    | • |   | New business acquisitions generate significant intangible assets that result in substantial related amortization charges to us and possible impairments.                                                                                                                                           |

----

----

----

----

|   | • |   | extend the reach of our products and services to a larger number of physicians and hospitals and to other participants in the healthcare industry; |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|   | • |   | develop and deploy new products and services;                                                                                                      |
|   | • |   | further enhance the MedLink brand; and                                                                                                             |
|   | • |   | generate additional revenue and cash flows.                                                                                                        |

|   | • |   | harm to our reputation;                                          |
|--------|---------|--------|------------------------------------------------------------------|
|   | • |   | lost sales;                                                      |
|   | • |   | delays in commercial release;                                    |
|   | • |   | product liability claims;                                        |
|   | • |   | delays in or loss of market acceptance of our solutions;         |
|   | • |   | license terminations or renegotiations; and                      |
|   | • |   | unexpected expenses and diversion of resources to remedy errors. |

----

|         | • |   | breadth and depth of services;      |
|--------------|---------|--------|-------------------------------------|
|    | • |   | reputation;                         |
|    | • |   | reliability, accuracy and security; |
|    | • |   | client service;                     |
|    | • |   | price; and                          |
|    | • |   | industry expertise and experience.  |

----

----

|   | • |   | Patient Information. As part of the operation of our business, our customers provide to us patient-identifiable medical information related to the prescription drugs that they prescribe and other aspects of patient treatment. Government and industry legislation andrulemaking, especially the Health Insurance Portability and Accountability Act of 1996 (HIPAA), and standards and requirements published by industry groups such as the Joint Commission on Accreditation of Healthcare Organizations, require the use of  standard transactions, standard identifiers, security and other standards and requirements for the transmission of certain electronic health information. National standards and procedures under HIPAA include the “Standardsfor Electronic Transactions and Code Sets” (the Transaction Standards); the “Security Standards” (the Security Standards); and the “Standards for Privacy of Individually Identifiable Health Information” (the Privacy Standards). The Transaction Standards require the use of specified data coding, formatting and content in all specified “Health Care Transactions”conducted electronically. The Security Standards require the adoption of specified types of security for healthcare information. The Privacy Standards grant a number of rights to individuals as to their identifiable confidential medical information (called Protected Health Information) and restrict the use and disclosure of Protected Health Information by Covered Entities, defined as “health care providers, health care payers, and health care clearinghouses.” Generally, the HIPAA standards directlyaffect Covered Entities. We have reviewed our activities and believe that we are a Covered Entity to the extent that we maintain a “group health plan” for the benefit of our employees. Such a plan, even if not a separate legal entity from us as its sponsor, is included in the HIPAA definition of Covered Entities. We have taken steps we believe to be appropriate and required to bring our group health plan into compliance with HIPAA. We do not believe that we are a Covered Entity as a health care provideror as a health care clearinghouse; however, the definition of a health care clearinghouse is broad and we cannot offer any assurance that we could not be considered a health care clearinghouse under HIPAA or that, if we are determined to be a healthcare clearinghouse; the consequences would not be adverse to our business, financial condition and results of operations. In addition, the Privacy and Security Standards affect third parties that create, access, or receive Protected Health Information in order to performa function or activity on behalf of a Covered Entity. Such third parties are called “Business Associates.” Covered Entities must have a written “Business Associate Agreement” with such third parties, containing specified written satisfactory assurances, consistent with the Privacy and Security standards, that the third party will safeguard Protected Health Information that it creates or accesses and will fulfill other material obligations to support the Covered Entity’s own HIPAAcompliance. Most of our customers are Covered Entities, and we function in many of our relationships as a Business Associate of those customers. We would face liability under our Business Associate Agreements if we do not comply with our Business Associate obligations. In addition, the federal agencies with enforcement authority have taken the position that a Covered Entity can be subject to HIPAA civil penalties and sanctions for a breach of a Business Associate Agreement. The penalties for a violation of HIPAAby a Covered Entity are significant and could have an adverse impact upon our business, financial condition and results of operations, if such penalties ever were imposed. Additionally, Covered Entities will be required to adopt a unique standard National Provider Identifier (NPI) for use in filing and processing health care claims and other transactions. Subject to the discussion set forth above, we believe that the principal effects of HIPAA are, first, to require that our systems be capable of being operatedby our customers in a manner that is compliant with the various HIPAA standards and, second, to require us to enter into and comply with Business Associate Agreements with our Covered Entity customers. For most Covered Entities, the deadlines for compliance with the Privacy Standards and the Transaction Standards occurred in 2003. Covered Entities, with the exception of small health plans (as that term is defined by the Privacy Standards), were required to be in compliance with the Security Standards by April 20,2005 and to use NPIs in standard transactions no later than the compliance dates, which are May 23, 2007 for all but small health plans and one year later for small health plans. We have policies and procedures that we believe assure compliance with all federal and state confidentiality requirements for the handling of Protected Health Information that we receive and with our obligations under Business Associate Agreements. In particular, we believe that our systems and products are capable of being usedby our customers in compliance with the Transaction Standards and Security Standards and are, or will be, capable of being used by our customers in compliance with the NPI requirements. If, however, we do not follow those procedures and policies, or they are not sufficient to prevent the unauthorized disclosure of Protected Health Information, we could be subject to liability, fines and lawsuits, termination of our customer contracts or our operations could be shut down. Moreover, because all HIPAA Standardsare subject to change or interpretation and because certain other HIPAA Standards, not discussed above, are not yet published, we cannot predict the full future impact of HIPAA on our business and operations. In the event that the HIPAA standards and compliance requirements change or are interpreted in a way that requires any material change to the way in which we do business, our business, financial condition and results of operations could be adversely affected. Additionally, certain state laws are not preemptedby HIPAA and may impose independent obligations upon our customers or us. Additional legislation governing the acquisition, storage and transmission or other dissemination of health record information and other personal information, including social security numbers, has been proposed at both the state and federal level. Such legislation may require holders of such information to implement additional security, reporting or other measures that may require substantial expenditures and may impose liability for afailure to comply with such requirements. In many cases, such proposed state legislation includes provisions that are not preempted by HIPAA. There can be no assurance that changes to state or federal laws will not materially restrict the ability of providers to submit information from patient records using our products and services. |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|    | • |   | Electronic Prescribing. The use of our software by physicians to perform a variety of functions, including electronic prescribing, electronic routing of prescriptions to pharmacies and dispensing, is governed by state and federal law, including fraud and abuse laws.States have differing prescription format requirements, which we have programmed into our software. Many existing laws and regulations, when enacted, did not anticipate methods of e-commerce now being developed. While federal law and the laws of many states permit the electronic transmission of prescription orders, the laws of several states neither specifically permit nor specifically prohibit the practice. Given the rapid growth of electronic transactions in healthcare, and particularly the growth of the Internet,we expect the remaining states to directly address these areas with regulation in the near future. In addition, on November 7, 2005, the Department of Health and Human Services published its final “E-Prescribing and the Prescription Drug Program” regulations (E-Prescribing Regulations). These regulations are required by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and became effective beginning on January 1, 2006. The E-Prescribing Regulations consistof detailed standards and requirements, in addition to the HIPAA standards discussed above, for prescription and other information transmitted electronically in connection with a drug benefit covered by the MMA’s Prescription Drug Benefit. These standards cover not only transactions between prescribers and dispensers for prescriptions but also electronic eligibility and benefits inquiries and drug formulary and benefit coverage information. The standards apply to prescription drug plans participating inthe MMA’s Prescription Drug Benefit. Aspects of our clinical products are affected by such regulation because of the need of our customers to comply, as discussed above. Compliance with these regulations could be burdensome, time-consuming and expensive. We also could become subject to future legislation and regulations concerning the development and marketing of healthcare software systems. For example, regulatory authorities such as the U.S. Department of Health and Human Services’ Center for Medicareand Medicaid Services may impose functionality standards with regard to electronic prescribing and EHR technologies. These could increase the cost and time necessary to market new services and could affect us in other respects not presently foreseeable. |
|--------------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | • |   | Electronic Health Records. A number of important federal and state laws govern the use and content of electronic health record systems, including fraud and abuse laws that may affect the donation of such technology.As a company that provides EHR systems to a variety of providers of healthcare, our systems and services must be designed in a manner that facilitates our customers’ compliance with these laws. Because this is a topic of increasing state and federal regulation, we must continue to monitor legislative and regulatory developments that might affect our business practices as they relate to EHR systems. We cannot predict the content or effect of possible future regulation on our business practices.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

----

----

|   | - | difficulty in integrating the acquired operations and retaining acquired personnel; |
|--------|---|-------------------------------------------------------------------------------------|

|   | - | diversion of management's attention and disruption of the Company’s ongoing business; and |
|--------|---|-------------------------------------------------------------------------------------------------|

----

----

----

|   | - | control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; |
|--------|---|-------------------------------------------------------------------------------------------------------------------------|

|   | - | manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; |
|--------|---|---------------------------------------------------------------------------------------------------------------------|

|   | - | “boiler room” practices involving high pressure sales tactics and unrealistic price projections by inexperienced sales persons; |
|--------|---|---------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and |
|--------|---|--------------------------------------------------------------------------------------------|

|   | - | the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses. |
|--------|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Item 

Item 

----

Item 

Item 

Item 

|   |   |   | High              | Low |
|--------|--------|--------|------------------------------------------------------------------------------------|-----|

|   | 1st Quarter 2007 | - | $0.97 | $0.27 |
|--------|------------------|---|-------|-------|

|   | 2nd Quarter 2007 | - | $2.04 | $0.72 |
|--------|------------------|---|-------|-------|

|   | 3rd Quarter 2007 | - | $1.50 | $0.86 |
|--------|------------------|---|-------|-------|

|   | 4th Quarter 2007 | - | $1.74 | $1.01 |
|--------|------------------|---|-------|-------|

|   | 1st Quarter 2008 | - | $1.50 | $0.71 |
|--------|------------------|---|-------|-------|

|   | 2nd Quarter 2008 | - | $1.25 | $0.71 |
|--------|------------------|---|-------|-------|

|   | 3rd Quarter 2008 | - | $1.76 | $0.50 |
|--------|------------------|---|-------|-------|

|   | 4th Quarter 2008 | - | $2.00 | $0.65 |
|--------|------------------|---|-------|-------|

|   | 1st Quarter 2009 | - | $1.00 | $0.35 |
|--------|------------------|---|-------|-------|

----

| (a)   | Equity Compensation Plan Information |
|-----------------|--------------------------------------|

| (b)   | The following table contains information concerning the Company's only existing equity compensation plans which cover certain officers, employees and consultants.  Each of the officers and consultants entered into an agreement with the Company for the provision of services which obligates the Company to pay option compensation. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Plan category                                                  | Number of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance |
|----------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------|
|                                                           | (a)                                                                                         | (b)                                                                         | (c)                                                          |
| Equity compensation plans approved by security holders         |                                                                                        |                                                                        |                                                         |
| Equity compensation plans not approved by security holders (1) | 2,000,000 (2,)                                                                              | $0.415                                                                      | 2,000,000 (1)7,603,013 (1)                              |
| Total                                                          | 2,000,000                                                                                   |                                                                        | 9,603,013                                                    |

----

| Jameson Rose      |   |   | 800,000   |
|-------------------|--------|--------|-----------|
| Ray Vuono         |   |   | 960,000   |
| Dr. Michael Carvo |   |   | 0         |
| Konrad Kim        |   |   | 240,000   |
|              |   |   |      |
|              |   |   | 2,000,000 |

|       | Salary    | Salary    | Salary    |
|------------|-----------|-----------|-----------|
|       | 2008      | 2009      | 2010      |
| Ray Vuono  | 1,376,400 | 1,651,680 | 1,982,016 |
| James Rose | 1,164,707 | 1,397,648 | 1,677,177 |
| Konrad Kim | 338,824   | 406,585   | 487,907   |
|       |      |      |      |
| Totals     | 2,879,931 | 3,455,913 | 4,147,100 |

|       | Options   | Options   | Options   |
|------------|-----------|-----------|-----------|
|       | 2008      | 2009      | 2010      |
| Ray Vuono  | 480,000   | 480,000   | 480,000   |
| James Rose | 400,000   | 400,000   | 400,000   |
| Konrad Kim | 120,000   | 120,000   | 120,000   |
| Totals     | 1,000,000 | 1,000,000 | 1,000,000 |

----

Item 

Item 

----

----

----

----

----

----

| ·   | Currently, out of the estimated 600,000 physicians in the U.S., only 15-20% are estimated to have employed EHRs for their practice. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| ·   | This market is expected to grow significantly in the next several years as legislation and federal directives drive EHR adoption among physicians. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | The Bush Administration mandated that physicians switch all patient records to electronic form by 2014.  The mandate has received bi-partisan support from Congress and President Obama; |
|--------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | Medicare Electronic Medication and Safety Protection Act provides financial incentives for physicians to use e-prescribing systems that have current year CCHIT certification; |
|--------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | Medicare Prescription Drug, Improvement, and Modernization Act of 2003 permits hospitals and other organizations to provide e-prescribing and EHR software, information technology and training services to physicians; and |
|--------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | Private and public initiatives for healthcare IT adoption have currently made available more than $700 million.  The majority of subsidies and grants require current year CCHIT certification. |
|--------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | -   More than $20 billion was provided for the adoption of healthcare IT in early 2009 |
|--------|-------------------------------------------------------------------------------------------------------|

| ·   | The Company has received endorsements from one of the largest medical associations in the U.S. as well as four New York based medical societies. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   |  The Company continues to form valuable strategic partnerships with imaging centers, laboratories, RHIO’s and other facilities through the integration of their systems with the Company’s EHR. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The Company’s value-added partners provide a “captive” base of physicians as customers for the Company’s products. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The Company has a focused sales and marketing effort underway to leverage this prime access opportunity to reach these physicians. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | The primary barrier to EHR adoption among physicians is cost.  The Company offers an attractive value proposition through MedLink EHR and EHR Lite.  EHR Lite provides physicians with basic EMR functionality at no upfront cost to the physician, creating a sticking point for later full EHR conversion. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The Company’s EHR is priced below competing products with similar services. |
|--------------------|-----------------------------------------------------------------------------------|

| ·   | Quick deployment of the Company’s EHR, makes the product very attractive to physicians and counterparties. |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| ·   | The Company’s EHR was one of 8 products which received full certification in October, 2008. |
|--------------------|---------------------------------------------------------------------------------------------------|

| ·   | This certification creates a tremendous competitive advantage for the Company in its targeted customer base, the small to medium sized physician office marketplace, as financial incentives are available to providers who use a 2008 CCHIT certified EHR product. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | 2% in fiscal year 2009 and 2010 |
|--------------------|---------------------------------|

| ·   | 1% in 2011 and 2012 |
|--------------------|---------------------|

| ·   | 0.5% in 2013 |
|--------------------|--------------|

| ·   | 1% payment cut in 2012 |
|--------------------|------------------------|

| ·   | 1.5% payment cut in 2013 |
|--------------------|--------------------------|

| ·   | 2% in subsequent years |
|--------------------|------------------------|

----

----

----

----

----

----

|                                                      |   |   |    |   | Less than |   |    |   |   |   |
|-----------------------------------------------------------|--------|--------|---------|--------|-----------|--------|---------|--------|--------|--------|
|                                                      | Total  |   | 1 year  |   | 1-3 years |
|                                                      |   |   |    |   |      |   |    |   |   |
|      Operating lease obligations |   | $      | 850,992 |   |      | $      | 129,500 |   |   | $      | 460,032 |   |

----

----

| 1)   | In evaluating the collectability of our accounts receivable, we assess a number of factors, including a specific client’s ability to meet its financial obligations to us, as well as general factors such as the length of time the receivables are past due and historical collection experience. Based on these assessments, we record a reserve for specificaccount balances as well as a reserve based on our historical experience for bad debt to reduce the related receivables to the amount we ultimately expect to collect from clients. If circumstances related to specific clients change, or economic conditions deteriorate such that our past collection experience is no longer relevant, our estimate of the recoverability of our accounts receivable could be further reduced from the levels provided for in the Consolidated Financial Statements. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Item 

----

Item 

|                                                                                                           | Page No. |
|----------------------------------------------------------------------------------------------------------------|----------|
| Report of Independent Registered Public Accounting Firm                                                        | 64       |
|                                                                                                           |     |
| Financial Statements                                                                                           |     |
| Consolidated Balance Sheets at December 31, 2008 and 2007                                                 | 65       |
| Consolidated Statements of Operations for the years ended December 31, 2008 and 2007                      | 66       |
| Consolidated Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2008 and 2007  | 67       |
| Consolidated Statements of Cash Flows for the years ended December 31, 2008 and 2007                      | 68       |
| Notes to Consolidated Financial Statements                                                      | 71       |

----

----

|                                                                                                                       |   | For the years ended |        |
|----------------------------------------------------------------------------------------------------------------------------|--------|---------------------|-------------|
|                                                                                                                       |   | December 31,        |        |
|                                                                                                                       |   | 2008                |        |   | 2007 |   |
| ASSETS                                                                                                                     |   |                |        |   |   |   |
| CURRENT ASSETS:                                                                                                            |   |                |        |   |   |   |
| Cash                                                                                                                       |   |                |        |   |   | 2,762 |   |
| Accounts Receivable                                                                                                        |   |                | 20,731      |   |   |   |   |   |
| Due from related party                                                                                                     |   |                | -           |   |   |   | 39,372 |   |
| Inventory                                                                                                                  |   |                | 2,818       |   |   |   |   |   |
| Deposits                                                                                                                   |   |                | 9,165       |   |   |   |   |   |
| Total current assets                                                                                                       |   |                | 32,714      |   |   |   | 42,134 |   |
|                                                                                                                       |   |                |        |   |   |   |   |   |
| Office equipment (at cost) net of accumulated depreciation                                                                 |   |                | 179,025     |   |   |   | 133,559 |   |
| Intangible asset (at cost), net of accumulated amortization                                                                |   |                | 40,450      |   |   |   | 41,538 |   |
| Goodwill                                                                                                                   |   |                | 1,252,129   |   |   |   | 1,252,129 |   |
| Security deposit                                                                                                           |   |                | 20,438      |   |   |   | 5,400 |   |
| Other assets                                                                                                               |   |                | 5,400       |   |   |   |   |   |
|                                                                                                                       |   |                |        |   |   |   |   |   |
| TOTAL ASSETS:                                                                                                              |   | $                   | 1,530,156   |   |   | $ | 1,474,760 |   |
|                                                                                                                       |   |                |        |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                       |   |                |        |   |   |   |   |   |
| CURRENT LIABILITIES:                                                                                                       |   |                |        |   |   |   |   |   |
| Accounts payable and accrued expenses                                                                                      |   |                | 403,277     |   |   |   | 427,683 |   |
| Bank overdraft                                                                                                             |   |                | 26,834      |   |   |   | - |   |
| Deferred revenue                                                                                                           |   |                | 70,384      |   |   |   | 64,884 |   |
| Current portion of capitalized lease payable                                                                               |   |                | 5,500       |   |   |   | 5,50 |   |
| Note payable                                                                                                               |   |                | 701,145     |   |   |   | 623,437 |   |
| Due to related party                                                                                                       |   |                | 1,002,988   |   |   |   | 533,922 |   |
| TOTAL CURRENT LIABILITIES                                                                                                  |   |                | 2,210,138   |   |   |   | 1,658,176 |   |
|                                                                                                                       |   |                |        |   |   |   |   |   |
| Stockholders' deficit:                                                                                                     |   |                |        |   |   |   |   |   |
| Common stock Class A $.001 par value; authorized 150,000,000 shares; 26,864,189 and 26,947,333 shares issued, respectively |   |                | 26,947      |   |   |   | 20,372 |   |
| Common stock B Class B $.001 par value; authorized 50,000,000; 5,361,876 issued and outstanding                            |   |                | 5,362       |   |   |   | 5,362 |   |
| Subscription receivable                                                                                                    |   |                | (300,000    | ) |   |   | (100,000 | ) |
| Additional paid-in capital                                                                                                 |   |                | 17,371,500  |   |   |   | 13,349,010 |   |
| Accumulated deficit                                                                                                        |   |                | (17,653,240 | ) |   |   | (13,287,741 | ) |
| Deferred charges                                                                                                           |   |                | 0           |   |   |   | (40,138 | ) |
| Treasury stock                                                                                                             |   |                | (130,551    | ) |   |   | (130,551 | ) |
| Total stockholders' deficit                                                                                                |   |                | (679,982    | ) |   |   | (183,416 | ) |
| TOTAL STOCKHOLDERS’ LIABILITIES AND STOCKHOLDER EQUITY                                                               |   | $                   | 1,530,156   |   |   | $ | 1,474,760 |   |

----

|                                                          |   | For the years ended |       |
|---------------------------------------------------------------|--------|---------------------|------------|
|                                                          |   | December 31,        |       |
|                                                          |   | 2008                |       |   | 2007 |   |
| Sales                                                         |   | $                   | 480,609    |   |   | $ | 280,022 |   |
| Cost of Revenues                                              |   |                | 18,935     |   |   |   | - |   |
| Gross Profit                                                  |   |                | 461,674    |   |   |   | 280,022 |   |
|                                                          |   |                |       |   |   |   |   |   |
| Operating expenses                                            |   |                |       |   |   |   |   |   |
| General and administrative                                    |   |                | 1,576,824  |   |   |   | 2,764,048 |   |
| Consulting expense                                            |   |                | 1,300,427  |   |   |   | - |   |
| Compensation expense                                          |   |                | 1,927,749  |   |   |   | - |   |
| Depreciation and amortization                                 |   |                | 22,443     |   |   |   | - |   |
| Total Operating expenses                                      |   |                | 4,827,443  |   |   |   | 2,809,908 |   |
|                                                          |   |                |       |   |   |   |   |   |
| Operating loss before minority interest                       |   |                | (4,365,769 | ) |   |   | (2,518,886 | ) |
|                                                          |   |                |       |   |   |   |   |   |
| Minority Interest                                             |   |                | -          |   |   |   | 56,507 |   |
| Net Loss                                                      |   | $                   | (4,365,769 | ) |   | $ | (2,462,829 | ) |
|                                                          |   |                |       |   |   |   |   |   |
| Basic and diluted loss per share (Class A)                    |   | $                   | (.15       | ) |   |   | (.12 | ) |
|                                                          |   |                |       |   |   |   |   |   |
| Basic and diluted loss per share (Class B)                    |   | $                   | (.81       | ) |   |   | (.46 | ) |
|                                                          |   |                |       |   |   |   |   |   |
| Weighted average number of basic shares outstanding (Class A) |   |                | 29,863,620 |   |   |   | 21,268,394 |   |
|                                                          |   |                |       |   |   |   |   |   |
| Weighted average number of basic shares outstanding (Class B) |   |                | 5,361876   |   |   |   | 5,361876 |   |
|                                                          |   |                |       |   |   |   |   |   |

----

|                                                                         | Common Stock     | Additional    |              |                |             |            |             |
|------------------------------------------------------------------------------|------------------|---------------|-------------------|---------------------|------------------|-----------------|------------------|
|                                                                         | Number of        |          | Paid-in           |                | Surplus          | Deferred        | Treasury         |   |
|                                                                         | Shares           | Amount        | Capital           | (Deficit)           | Receivables      | Charges         | Stock            | Total |
| Balance at December 31, 2006                                                 | 16,646,822       | $16,647       | $10,730,165       | $(10,824,642)       | $(19,783)        | $(159,538)      | $(130,551)       | $(387,702) |
| Share issued for employment  services                              | 2,400,000        | 2,400         | 324,000           | 0                   | 0                | 0               | 0                | 326,400 |
| Stock based compensation                                                     | 0                | 0             | 400,000           | 0                   | 0                | 0               | 0                | 400,000 |
| Repayment of receivables                                                     | 0                | 0             | 0                 | 0                   | 19,783           | 0               | 0                | 19,783 |
| Shares issued in connection with the exercise of shareholders’ options |  1,480,000  |  1,480   |  250,120     |  0             |  0          |  0         |  0          |  251,600 |
| Shares issued for consulting services                                        | 50,000           | 50            | 45,725            | 0                   | 0                | 0               | 0                | 45,775 |
| Shares sold in 2007                                                          | 4,956,876        | 4,957         | 1,122,874         | 0                   | (100,000)        | 0               | 0                | 1,027,831 |
| Options issued for consultants service                                       | 0                | 0             | 176,326           | 0                   | 0                | 0               | 0                | 176,326 |
| Deferred charges                                                             | 0                | 0             | 0                 | 0                   | 0                | 119,400         | 0                | 119,400 |
| Shares issued in Anywhere MD acquisition                                     |  200,000    |  200     |  299,800     |  0             |  0          |  0         |  0          |  300,000 |
|                                                                         |             |          |              |                |             |            |             |   |
| Net loss for the year ended     December 31, 2007   |  0          |  0       |  0           |  (2,462,829)   |  0          |  0         |  0          |  (2,462,829) |
|  Balance at December 31, 2007                                           |  25,733,698 |  $25,734 |  $13,349,010 |  $(13,287,471) |  $(100,000) |  $(40,138) |  $(130,551) |  $((183,416) |
| Share issued for employment  services                              | 2,879,999        | 2,880         | 388,800           | 0                   | 0                | 0               | 0                | 391,680 |
| Shares issued for consultants services                                       | 2,407,000        | 2,407         | 2,426,813         | 0                   | 0                | 0               | 0                | 2,429,220 |
| Shares issued for payables                                                   | 43,930           | 44            | 43,886            | 0                   | 0                | 0               | 0                | 43,930 |
| Shares issued to settle loan payable                                         | 560,000          | 560           | 279,440           | 0                   | 0                | 0               | 0                | 280,000 |
| Stock based compensation                                                     | 0                | 0             | 533,345           | 0                   | 0                | 0               | 0                | 533,345 |
| Shares issued in lieu of rent                                                | 55,000           | 55            | 28,652            | 0                   | 0                | 0               | 0                | 28,707 |
| Shares issued for legal fee’s                                          | 100,000          | 100           | 112,083           | 0                   | 0                | 0               | 0                | 112,183 |
| Shares issued in connection with the exercise of shareholders’ options | 117,989          | 118           | (118)             | 0                   | 0                | 0               | 0                | 0 |
| Shares sold in 2008                                                          | 411,593          | 411           | 209,589           | 0                   | (200,000)        | 0               | 0                | 10,000 |
| Net deficit acquired in Anywhere   MD                         | 0                | 0             | 0                 | 0                   | 0                | 40,138          | 0                | 40,138 |
| Net loss for the year endedDecember 31, 2008                                 |  0          |  0       |  0           |  (4,365,769)   |  0          |  0         |  0          |  (4,365,769) |
|  Balance at December 31, 2008                                           |  32,309,209 |  $32,310 |  $17,371,500 |  $(17,653,240) |  $(300,000) |  $0        |  $(130,551) |  $(679,982) |

----

|                                                                           |   | For the years ended |       |
|--------------------------------------------------------------------------------|--------|---------------------|------------|
|                                                                           |   | December 31,        |       |
|                                                                           |   | 2008                |       |   | 2007 |   |
| Cash flows from operating activities:                                          |   |                |       |   |   |   |
| Net loss                                                                       |   | $                   | (4,365,769 | ) |   | $ | (2,462,829 | ) |
| Adjustments to reconcile net loss  to net cash                       |   |                |       |   |   |   |   |   |
| used in operating activities:                                                  |   |                |       |   |   |   |   |   |
|      Minority interest                                |   |                | -          |   |   |   | (113,290 | ) |
|      Depreciation                                     |   |                | 22,443     |   |   |   | 34,860 |   |
|      Increase in deferred charges                     |   |                | 40,138     |   |   |   | - |   |
|      Amortization                                     |   |                | 1,088      |   |   |   | 0 |   |
|      Amortization of deferred charges                 |   |                | -          |   |   |   | 132,163 |   |
|          Issuance of common stock |   |                | 210,000    |   |   |   | - |   |
|      Share based compensation                         |   |                | 533,345    |   |   |   | 400,000 |   |
|      Issuance of common stock for salary              |   |                | 391,680    |   |   |   | - |   |
| Issuance of common shares for consulting and other services rendered           |   |                | 2,429,220  |   |   |   | 819,884 |   |
| Issuance of common stock for relief of loans                                   |   |                | 323,930    |   |   |   | - |   |
| Issuance of common stock for rent                                              |   |                | 28,707     |   |   |   | - |   |
| Issuance of common stock for legal fees                                        |   |                | 112,183    |   |   |   | - |   |
| Inventory                                                                      |   |                | (2,818     | ) |   |   | - |   |
| Deposits                                                                       |   |                | (9,165     | ) |   |   | (12,583 | ) |
| Increase in deferred revenue                                                   |   |                | 5,500      |   |   |   | 64,884 |   |
| Accounts receivable                                                            |   |                | (15,731    | ) |   |   | (39,372 | ) |
| Other assets                                                                   |   |                | (20,438    | ) |   |   |   |   |
| Accrued expense and other current liabilities                                  |   |                | (24,406    | ) |   |   | (37,537 | ) |
|                                                                           |   |                |       |   |   |   |   |   |
| Net cash used in operating activities                                          |   |                | (345,093   | ) |   |   | (1,213,820 | ) |
|                                                                           |   |                |       |   |   |   |   |   |
| Cash flows from investing activities:                                          |   |                |       |   |   |   |   |   |
| Purchase of fixed assets                                                       |   |                | (67,909    | ) |   |   | (111,685 | ) |
| Purchase of intangible asset                                                   |   |                | 0          |   |   |   | (41,812 | ) |
| Cash acquired in Med-Link acquisition                                          |   |                | -          |   |   |   | 274 |   |
|                                                                           |   |                |       |   |   |   |   |   |
| Net cash used in investing activities                                          |   |                | (67,909    | ) |   |   | (153,223 | ) |

----

|                                                                                        |   | For the years ended |      |
|---------------------------------------------------------------------------------------------|--------|---------------------|-----------|
|                                                                                        |   | December 31,        |      |
|                                                                                        |   | 2008                |      |   | 2007 |   |
|   Cash flows from financing activities:                                           |   |                |      |   |   |   |
| Proceeds from related party loans                                                           |   |                | -         |   |   |   |   |
| Repayment of loans                                                                          |   |                | -         |   |   |   | (251,563 | ) |
| Increase in lease payable                                                                   |   |                | (2,750    | ) |   |   | (5,500 | ) |
| Proceeds from loan payable                                                                  |   |                | 77,708    |   |   |   | - |   |
| Proceeds from sale of stock                                                                 |   |                | -         |   |   |   | 1,027,831 |   |
| Proceeds from subscription receivable                                                       |   |                | (200,000  | ) |   |   |   |   |
| Advances from (to) officer/shareholders                                                     |   |                | 508,448   |   |   |   | 599,037 |   |
|                                                                                        |   |                |      |   |   |   |   |   |
| Net cash provided by (financing activities                                                  |   |                | 383,406   |   |   |   | 1,369,805 |   |
|                                                                                        |   |                |      |   |   |   |   |   |
| NET INCREASE (DECREASE) IN CASH                                                             |   |                | (29,596   | ) |   |   | 2,762 |   |
|                                                                                        |   |                |      |   |   |   |   |   |
| CASH AT BEGINNING OF YEAR                                                                   |   |                | 2,762     |   |   |   | - |   |
|                                                                                        |   |                |      |   |   |   |   |   |
| CASH AT END OF PERIOD                                                                       |   | $                   | (26,834   | ) |   | $ | 2,762 |   |
|                                                                                        |   |                |      |   |   |   |   |   |
| Supplemental disclosure of cash flow information:                                           |   |                |      |   |   |   |   |   |
| Cash paid during the year for interest                                                      |   | $                   | -         |   |   | $ | - |   |
| Cash paid for taxes                                                                         |   | $                   | -         |   |   | $ | - |   |
|                                                                                        |   |                |      |   |   |   |   |   |
| Supplemental disclosure of non-cash financing activities                                    |   |                |      |   |   |   |   |   |
| Issuance of common stock                                                                    |   | $                   | 210,000   |   |   | $ | - |   |
| Share based compensation                                                                    |   | $                   | 533,345   |   |   | $ | - |   |
| Issuance of common stock for salary                                                         |   | $                   | 391,680   |   |   | $ | - |   |
| Issuance of common shares for consulting and other    services rendered |   | $                   | 2,429,220 |   |   | $ | - |   |
| Issuance of common stock for relief of loans                                                |   | $                   | 323,930   |   |   | $ | - |   |
| Issuance of common stock for rent                                                           |   | $                   | 28,707    |   |   | $ | - |   |
| Issuance of common stock for legal fees                                                     |   | $                   | 112,183   |   |   | $ | - |   |

----

|                                                     |   | For the years ended |   |
|----------------------------------------------------------|--------|---------------------|--------|
|                                                     |   | December 31,        |   |
|                                                     |   | 2008                |   |   | 2007 |   |
| Supplemental disclosures of cash flows information: |   |                |   |   |   |   |
|   Cash paid during the year for:               |   |                |   |   |   |   |
| Interest                                                 |   | $                   | 0      |   |   | $ | 0 |   |
| Income Taxes                                             |   | $                   | 0      |   |   | $ | 1,700 |   |
|                                                     |   |                |   |   |   |   |   |   |

----

----

----

----

----

----

----

----

----

| ·   | 62.5% of the operating activity of Anywhere from the period of May 14, 2007 through December 29, 2007 |
|--------------------|-------------------------------------------------------------------------------------------------------|

| ·   | 100% of the operating activity of Anywhere from the period of December 30, 2007 through December 31, 2007. |
|--------------------|------------------------------------------------------------------------------------------------------------|

| ·   | On May 14, 2007, the Company 100% of the purchase price of $975,000 to goodwill. |
|--------------------|----------------------------------------------------------------------------------|

| ·   | On December 30, 2007 the Company purchased all of the assets and assumed certain liabilities of Anywhere MD in exchange for 200,000 shares of the Company’s common stock.  Such shares were valued at $1.50, which was the fair market value as of December 30, 2007, less expenses of approximately $23,000. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          |   | Estimated Useful |   |   | 2008   |   |    | 2007   |   |
|-------------------------------|--------|------------------|--------|--------|--------|--------|---------|--------|--------|
|                          |   | life (years)     |   |   | Amount |   |    | Amount |   |
| Furniture and fixtures        |   |             | 5      |   |   | $      | 32,174  |   |   |   | 13,320 |   |
| Leasehold improvements        |   |             | 3      |   |   |   | 10,423  |   |   |   | 10,423 |   |
| Equipment                     |   |             | 5      |   |   |   | 245,955 |   |   |   | 196,900 |   |
|                          |   |             |   |   |   |   | 288,552 |   |   |   | 260,643 |   |
| Less accumulated depreciation |   |             |   |   |   |   | 109,527 |   |   |   | 87,084 |   |
|                          |   |             |   |   |   |   |    |   |   |   |   |   |
|                          |   |             |   |   |   | $      | 179,025 |   |   | $ | 133,559 |   |

----

|                                                                                                                                                                              |   | 2008   |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
| Notes payable to a finance company, due in monthly installments of $540, including principal, sales tax & interest at 8.5% through 2009, collateralized by certain equipment. |   | $      | 5,500  |   |
| Less current portion                                                                                                                                                              |   |   | (5.500 | ) |
| Long – term debt                                                                                                                                                            |   | $      | 0      |   |
|                                                                                                                                                                              |   |   |   |   |

| Stock-based compensation:                                                 |   | 2008   |      |   | 2007   |   |
|---------------------------------------------------------------------------|--------|--------|-----------|--------|--------|--------|
| MedLink Employee, officers and directors stock-based compensation expense |   | $      | 391,608   |   |   |   | 326,400 |   |
| Total stock-based compensation                                            |   |   | 2,879,000 |   |   |   | 2,400,000 |   |

----

| Consultant stock-based compensation:        |   | 2008   |      |   | 2007   |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|
| Consultant stock-based compensation expense |   | $      | 2,429,220 |   |   |   | 45,775 |   |
| Total stock-based compensation              |   |   | 2,407,000 |   |   |   | 50,000 |   |

----

----

|                                      |      | Weighted Average | Weighted AverageRemaining | Aggregate Intrinsic |
|-------------------------------------------|-----------|------------------|---------------------------|---------------------|
|                                      | Shares    | Exercise Price   | Contractuallife in years  | Value               |
| Options outstanding as of January 1, 2007 | 1,490,000 | $0.17            |                      |                |
| Granted                                   | 1,540,000 | $0.31            |                      |                |
| Canceled/Forfeited                        |      |             |                      |                |
| Exercised                                 | 1,480,000 | $0.17            |                      |                |
| Options outstanding at December 31, 2007  | 1,550,000 | $0.31            | 6.4                       | $1,844,500          |
| Granted                                   | 1,000,000 | $0.85            |                      |                |
| Canceled/Forfeited                        | 87,011    | $0.31            |                      |                |
| Exercised                                 | 117,989   | $0.31            |                      |                |
| Option outstanding at December 31, 2008   | 2,345,000 | $0.54            | 7.6                       | $1,031,150          |

| j)   | Stock Options (continued) |
|----------------|---------------------------|

| Outstanding Options |        |             | Exercisable Options |
|---------------------|-------------|------------------|---------------------|
|                | Number of   | Average          | Average             | Number of | Average |
|                | Options     | Remaining        | Exercise            | Options | Exercise |
| Exercise Price      | Outstanding | Contractual Life | Price               | Outstanding | Price |
| $0.30               | 1,335,000   | 6.3              | $0.30               | 1,350,000 | $0.30 |
| $0.85               | 10,000      | 0.85             | $0.85               | 10,000 | $0.85 |
| $0.85               | 1,000,000   | 9.2              | $0.85               |   |   |

----

|                                          |   | 2008   |       |   | 2007   |   |
|-----------------------------------------------|--------|--------|------------|--------|--------|--------|
| Current:                                      |   |   |       |   |   |   |
| Federal and state                             |   | $      | 0          |   |   | $      | 0 |   |
| Deferred:                                     |   |   |       |   |   |   |   |   |
| Federal and state                             |   | $      | (1,746,308 | )      |   | $      | (1,510,967 | ) |
| Benefit from the operating loss carry forward |   | $      | 1,746,308  |   |   | $      | 1,510,967 |   |
|                                          |   |   |       |   |   |   |   |   |
| Benefit for income taxes, net                 |   | $      | 0          |   |   | $      | 0 |   |

|                              |   | 2008   |   |   | 2007   |   |
|-----------------------------------|--------|--------|--------|--------|--------|--------|
|                              |   |   |   |   |   |   |
| Statutory federal income tax rate |   |   | 34.0   | %      |   |   | 34.0 | % |
| State income taxes                |   |   | 6.0    | %      |   |   | 6.0 | % |
| Valuation allowance               |   |   | (40.0  | )%     |   |   | (40.0 | )% |
| Effective tax rate                |   |   | (0.0   | )%     |   |   | (0.0 | )% |

----

| Year ended December 31, |    |
|-------------------------|---------|
| 2009                    | $54,990 |
| 2010                    | $54,990 |
| 2011                    | $54,990 |
| 2012                    | $36,660 |

| Year ended December 31, |    |
|-------------------------|---------|
| 2009                    | $64,750 |
| 2010                    | $80,780 |
| 2011                    | $84,486 |
| 2012                    | $88,184 |
| 2013                    | $91,880 |
| 2014                    | $15,416 |

----

Item 

Item 

----

|   | · | Weakness: The Company’s board of directors has yet to pass a formal resolution to put in place a strategic plan and framework in order to comply with the regulations placed on issuers concerning internal controls. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Weakness: The Company lacks a comprehensive Code of Ethics that is applicable to the entire Company including officers, employees, and directors. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Weakness: The Company lacks a guideline that specifically states the objective and core functions of the Company so that there is no ambiguity to all members of the organization as to what type of business transactions the Company should be conducting. This guideline should also be reviewedon regular basis by management and the Board of Directors in order to address the ever changing business environment and the demands of the market. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | Weakness: The Company accounting department is currently understaffed and lacks personnel with expertise in US GAAP and SEC reporting standards. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Weakness: The Company does not have an internal audit function and department. |
|--------|--------|--------------------------------------------------------------------------------|

|   | · | Weakness: The Company does not have a standardized and unified Enterprise Resource Planning Software (ERP). The Company’s accounting systems are disparate and sometimes manual in nature which makes them neither scalable nor efficient for financial reporting purposes and managementdecision making needs. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Item 10. | Directors, Executive Officers, and Corporate Governance |
|----------|---------------------------------------------------------|

| Name              | Age    | Position                                                     | Director or Officer Since |
|-------------------|--------|--------------------------------------------------------------|---------------------------|
|              |   |                                                         |                      |
| Ray Vuono         | 43     | Chief Executive Officer, President and Chairman of the Board | January 1, 2004           |
|              |   |                                                         |                      |
| Konrad Kim        | 37     | Director and Chief Technology Officer                        | October 1, 2000           |
|              |   |                                                         |                      |
| Dr. Michael Carvo | 56     | Director                                                     | January 1, 2002           |
|              |   |                                                         |                      |
| James Rose        |   | Chief Financial Officer and Executive Vice President         | January 1, 2004           |
|              |   |                                                         |                      |
| James Decker      | 44     | Executive Vice President of Sales                            | July 1, 2006              |

----

----

| Item 11. | Executive Compensation |
|----------|------------------------|

| SUMMARY COMPENSATION TABLE  |
|-----------------------------|
|                        | Long Term Compensation |   |
|                        | Annual Compensation | Awards | Payouts |   |
|                        |   |   |   |   |   |   |   |   |
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Other Annual Compensation ($) | Restricted Stock Award(s) (#) | Securities Underlying Options/SARs (#) | LTIP Payouts ($) | All Other Compensation ($) |
| Ray Vuono, CEO (1)          | 2008 | $4,290 | $0 | $0 | 1,376,471 | 480,000 |   |   |
|                        | 2007 | $10,725 | $0 | $0 | 1,147,059 | 480,000 |   |   |
|                        | 2006 | $0 | $0 | $0 | 955,483 | 480,000 |   |   |
|                        |   |   |   |   |   |   |   |   |
| Jameson Rose, CFO (2)       | 2008 | $4,290 | $0 | $0 | 1,164,705 | 400,000 |   |   |
|                        | 2007 | $10,725 | $0 | $0 | 970,588 | 400,000 |   |   |
|                        | 2006 | $0 | $0 | $0 | 808,824 | 400,000 |   |   |
|                        |   |   |   |   |   |   |   |   |
| Konrad Kim, CTO (3)         | 2008 | $4,290 | $0 | $0 | 338,823 | 120,000 |   |   |
|                        | 2007 | $10,725 | $0 | $0 | 282,353 | 120,000 |   |   |
|                        | 2006 | $0 | $0 | $0 | 235,295 | 120,000 |   |   |

|   | (1) | Mr. Vuono received minimal cash payments at the minimum wage rate to qualify for the Company’s health benefits during the year ended December, 31, 2007 and 2008, but did receive 2,523,530 shares of common stock as payment in those years, in lieu of salary. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Mr. Rose received minimal cash payments at the minimum wage rate to qualify for the Company’s health benefits during the year ended December, 31, 2007 and 2008, but did receive 2,135,293 shares of common stock as payment in those years, in lieu of salary. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | Mr. Kim received minimal cash payments at the minimum wage rate to qualify for the Company’s health benefits during the year ended December, 31, 2007 and 2008, but did receive 621,176 shares of common stock as payment in those years, in lieu of salary. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|----------|------------------------------------------------------------------------------------------------|

| Title of Class | Name and Address of Beneficial Owner | Amount and Nature of Beneficial Ownership | Percent of Class |
|----------------|--------------------------------------|-------------------------------------------|------------------|
|           |                                 |                                      |             |
| $.001 par (1)  | Ray Vuono                            | 7,306,813                                 | 21.87%           |
| value per      | 1 Roebling Court                     |                                      |             |
| share          | Ronkonkoma, New York 11779           |                                      |             |
| common         |                                 |                                      |             |
|           |                                 |                                      |             |
| $.001 par (2)  | Jameson Rose                         | 6,298,797                                 | 18.85%           |
| value per      | 1 Roebling Court                     |                                      |             |
| share          | Ronkonkoma, New York 11779           |                                      |             |
| common         |                                 |                                      |             |
|           |                                 |                                      |             |
| $.001 par      | Jerry Bermensolo                     | 4,144,778                                 | 12.41%           |
| value per      | 1087 W. River St, Suite 280          |                                      |             |
| share          | Boise, ID 83702                      |                                      |             |
| common         |                                 |                                      |             |
|           |                                 |                                      |             |
|           |                                 |                                      |             |
| $.001 par (3)  | Konrad Kim                           | 1,823,055                                 | 5.46%            |
| value per      | 1 Roebling Court                     |                                      |             |
| share          | Ronkonkoma, New York 11779           |                                      |             |
| common         |                                 |                                      |             |
|           |                                 |                                      |             |
| $.001 par      | Dr. Michael Carvo, Director          | 472,676                                   | 1.41%            |
|           | 1 Roebling Court                     |                                      |             |
| share          | Ronkonkoma, New York 11779           |                                      |             |
| common         |                                 |                                      |             |
|           |                                 |                                      |             |
|           |                                 |                                      |             |
|           |                                 | 15,901,341                                | 47.60%           |

Item 

|   | Board Determination of Independence |
|--------|-------------------------------------|

|   |   |
|--------|--------|

----

Item 

|                   | 2008    | 2007    |
|------------------------|---------|---------|
|                   |    |    |
| Audit Related Fees     | $35,000 | $37,500 |
| Tax Fees               | $2,965  | $2,965  |
| All Other Fees         |    |    |
| Out-of-Pocket Expenses |    |    |
| Total                  | $37,965 | $40,465 |

Item 

----

| 10.10 | Employment Agreement between the Company and Ray Vuono dated January 1, 2004; (7) |
|-------|-----------------------------------------------------------------------------------|

----

----

SIGNATURES

----

| Name                                           | Percentage Ownership |
|------------------------------------------------|----------------------|
|                                           |                 |
| KRad Konsulting, LLC                           | 100%                 |
|                                           |                 |
| MedLink USA, Inc.                              | 100%                 |
|                                           |                 |
| Western Media Acquisition Corp.                | 100%                 |
| (Formerly Western Media Sports Holdings, Inc.) |                 |
|                                           |                 |
| Western Media Publishing Corporation           | 100%                 |
|                                           |                 |
| MedLink VPN, Inc.                              | 100%                 |
|                                           |                 |
| Norika USA, Inc.                               | 100%                 |
|                                           |                 |
| MedLink FE, Inc.                               | 100%                 |
|                                           |                 |
| MedLink India Software, Ltd.                   | 100%                 |

----

----